{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T16:37:27Z","timestamp":1792514247031,"version":"4.5.0"},"reference-count":78,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T00:00:00Z","timestamp":1775779200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T00:00:00Z","timestamp":1775779200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005639","name":"Universidade De S\u00e3o Paulo","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005639","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AAPS PharmSciTech"],"DOI":"10.1208\/s12249-026-03396-5","type":"journal-article","created":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T21:10:59Z","timestamp":1775855459000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Besifloxacin-Loaded Nanostructured Lipid Carrier for Ocular Delivery: Formulation Optimization, In Vitro Characterization, and Safety Assessment"],"prefix":"10.1208","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-9611-8432","authenticated-orcid":false,"given":"Mirla Anali Bazan","family":"Henostroza","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6486-0470","authenticated-orcid":false,"given":"J\u00e9ssica Fagionato","family":"Masiero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-2997-8306","authenticated-orcid":false,"given":"Carolina Falaschi","family":"Saponi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1814-2395","authenticated-orcid":false,"given":"Danielle Costa Vargas","family":"Redondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0919-0213","authenticated-orcid":false,"given":"Raimar","family":"L\u00f6benberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel Lima Barros","family":"de Araujo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5271-5468","authenticated-orcid":false,"given":"N\u00e1dia Araci","family":"Bou-Chacra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,10]]},"reference":[{"key":"3396_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.micpath.2020.104206","volume":"145","author":"KG Deepthi","year":"2020","unstructured":"Deepthi KG, Prabagaran SR. Ocular bacterial infections: pathogenesis and diagnosis. Microb Pathog. 2020;145:104206. https:\/\/doi.org\/10.1016\/j.micpath.2020.104206.","journal-title":"Microb Pathog"},{"key":"3396_CR2","doi-asserted-by":"publisher","DOI":"10.1186\/s12886-017-0612-2","volume":"17","author":"M Teweldemedhin","year":"2017","unstructured":"Teweldemedhin M, Gebreyesus H, Atsbaha AH, Asgedom SW, Saravanan M. Bacterial profile of ocular infections: a systematic review. BMC Ophthalmol. 2017;17:212.\nhttps:\/\/doi.org\/10.1186\/s12886-017-0612-2\n.","journal-title":"BMC Ophthalmol"},{"key":"3396_CR3","doi-asserted-by":"publisher","first-page":"67","DOI":"10.18773\/austprescr.2018.016","volume":"41","author":"S Watson","year":"2018","unstructured":"Watson S, Cabrera-Aguas M, Khoo P. Common eye infections. Aust Prescr. 2018;41:67\u201372.\nhttps:\/\/doi.org\/10.18773\/austprescr.2018.016\n.","journal-title":"Aust Prescr"},{"key":"3396_CR4","doi-asserted-by":"publisher","DOI":"10.1208\/s12249-023-02516-9","volume":"24","author":"S Ahmed","year":"2023","unstructured":"Ahmed S, Amin MM, Sayed S. Ocular drug delivery: a comprehensive review. AAPS PharmSciTech. 2023;24:66.\nhttps:\/\/doi.org\/10.1208\/s12249-023-02516-9\n.","journal-title":"AAPS PharmSciTech"},{"key":"3396_CR5","doi-asserted-by":"publisher","DOI":"10.3389\/fddev.2022.954771","author":"EM Del Amo","year":"2022","unstructured":"Del Amo EM. Topical ophthalmic administration: can a drug instilled onto the ocular surface exert an effect at the back of the eye? Frontiers in Drug Delivery. 2022.\nhttps:\/\/doi.org\/10.3389\/fddev.2022.954771\n.","journal-title":"Frontiers in Drug Delivery"},{"key":"3396_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jconrel.2020.01.057","volume":"321","author":"C Jumelle","year":"2020","unstructured":"Jumelle C, Gholizadeh S, Annabi N, Dana R. Advances and limitations of drug delivery systems formulated as eye drops. J Control Release. 2020;321:1\u201322.\nhttps:\/\/doi.org\/10.1016\/j.jconrel.2020.01.057\n.","journal-title":"J Control Release"},{"key":"3396_CR7","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.1016\/j.drudis.2019.02.001","volume":"24","author":"A Subrizi","year":"2019","unstructured":"Subrizi A, del Amo EM, Korzhikov-Vlakh V, Tennikova T, Ruponen M, Urtti A. Design principles of ocular drug delivery systems: importance of drug payload, release rate, and material properties. Drug Discov Today. 2019;24:1446\u201357. https:\/\/doi.org\/10.1016\/j.drudis.2019.02.001.","journal-title":"Drug Discov Today"},{"key":"3396_CR8","doi-asserted-by":"publisher","first-page":"25","DOI":"10.2147\/OPTO.S59013","volume":"6","author":"T Comstock","year":"2014","unstructured":"Comstock T, Morris T, Gearinger L, DeCory H. Clinical outcomes with besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis due to potentially consequential pathogens. Clin Optom (Auckl). 2014;6:25.\nhttps:\/\/doi.org\/10.2147\/OPTO.S59013\n.","journal-title":"Clin Optom (Auckl)"},{"key":"3396_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40123-016-0046-6","volume":"5","author":"FS Mah","year":"2016","unstructured":"Mah FS, Sanfilippo CM. Besifloxacin: efficacy and safety in treatment and prevention of ocular bacterial infections. Ophthalmol Ther. 2016;5:1\u201320.\nhttps:\/\/doi.org\/10.1007\/s40123-016-0046-6\n.","journal-title":"Ophthalmol Ther"},{"key":"3396_CR10","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/j.ajo.2011.03.010","volume":"152","author":"W Haas","year":"2011","unstructured":"Haas W, Pillar CM, Torres M, Morris TW, Sahm DF. Monitoring antibiotic resistance in ocular microorganisms: results from the Antibiotic Resistance Monitoring in Ocular MicRorganisms (ARMOR) 2009 surveillance study. Am J Ophthalmol. 2011;152:567-574.e3. https:\/\/doi.org\/10.1016\/j.ajo.2011.03.010.","journal-title":"Am J Ophthalmol"},{"key":"3396_CR11","unstructured":"Asbell PA. BESIVANCE\u00ae (besifloxacin ophthalmic suspension) 0.6%: a powerful option for the treatment of bacterial conjunctivitis. Ophthalmology Web. 2011. Available from: https:\/\/www.ophthalmologyweb.com\/139526-BESIVANCE-besifloxacin-ophthalmic-suspension-0-6-A-Powerful-Option-for-the-Treatment-of-Bacterial-Conjunctivitis\/.\u00a0Accessed 10 Mar 2026."},{"key":"3396_CR12","doi-asserted-by":"publisher","first-page":"83","DOI":"10.2165\/11203820-000000000-00000","volume":"70","author":"NJ Carter","year":"2010","unstructured":"Carter NJ, Scott LJ. Besifloxacin ophthalmic suspension 0.6%. Drugs. 2010;70:83\u201397. https:\/\/doi.org\/10.2165\/11203820-000000000-00000.","journal-title":"Drugs"},{"key":"3396_CR13","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.jcjo.2014.12.013","volume":"50","author":"J Desch\u00eanes","year":"2015","unstructured":"Desch\u00eanes J, Blondeau J. Besifloxacin in the management of bacterial infections of the ocular surface. Can J Ophthalmol. 2015;50:184\u201391.\nhttps:\/\/doi.org\/10.1016\/j.jcjo.2014.12.013\n.","journal-title":"Can J Ophthalmol"},{"key":"3396_CR14","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics11020204","volume":"11","author":"RP Kowalski","year":"2022","unstructured":"Kowalski RP, V.Nayyar S, Romanowski EG, Jhanji V. Anti-infective treatment and resistance is rarely problematic with eye infections. Antibiotics. 2022;11:204.\nhttps:\/\/doi.org\/10.3390\/antibiotics11020204\n.","journal-title":"Antibiotics"},{"key":"3396_CR15","first-page":"29","volume":"26","author":"AK Talukder","year":"2017","unstructured":"Talukder AK, Sultana Z, Jahan I, Khanam M, Rahman M, Rahman MF, et al. Antibiotic Resistance: New Challenge in the Management of Bacterial Eye Infections. Mymensingh Med J. 2017;26:29\u201336.","journal-title":"Mymensingh Med J"},{"key":"3396_CR16","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics10050593","volume":"10","author":"MF Varela","year":"2021","unstructured":"Varela MF, Stephen J, Lekshmi M, Ojha M, Wenzel N, Sanford LM, et al. Bacterial resistance to antimicrobial agents. Antibiotics. 2021;10:593. https:\/\/doi.org\/10.3390\/antibiotics10050593.","journal-title":"Antibiotics"},{"key":"3396_CR17","doi-asserted-by":"publisher","DOI":"10.3390\/ph16030474","volume":"16","author":"V Gugleva","year":"2023","unstructured":"Gugleva V, Andonova V. Recent progress of solid lipid nanoparticles and nanostructured lipid carriers as ocular drug delivery platforms. Pharmaceuticals. 2023;16:474.\nhttps:\/\/doi.org\/10.3390\/ph16030474\n.","journal-title":"Pharmaceuticals"},{"key":"3396_CR18","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14030586","volume":"14","author":"M Imran","year":"2022","unstructured":"Imran M, Jha SK, Hasan N, Insaf A, Shrestha J, Shrestha J, et al. Overcoming multidrug resistance of antibiotics via nanodelivery systems. Pharmaceutics. 2022;14:586. https:\/\/doi.org\/10.3390\/pharmaceutics14030586.","journal-title":"Pharmaceutics"},{"issue":"2","key":"3396_CR19","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/0003-2697(79)90222-7","volume":"100","author":"GL Peterson","year":"1979","unstructured":"Peterson GL. Review of the folin phenol protein quantitation method of Lowry, Rosebrough, Farr and Randall. Anal Biochem. 1979;100(2):201\u201320. https:\/\/doi.org\/10.1016\/0003-2697(79)90222-7.","journal-title":"Anal Biochem"},{"key":"3396_CR20","doi-asserted-by":"publisher","DOI":"10.3389\/fchem.2020.00286","author":"Y-C Yeh","year":"2020","unstructured":"Yeh Y-C, Huang T-H, Yang S-C, Chen C-C, Fang J-Y. Nano-based drug delivery or targeting to eradicate bacteria for infection mitigation: a review of recent advances. Front Chem. 2020.\nhttps:\/\/doi.org\/10.3389\/fchem.2020.00286\n.","journal-title":"Front Chem"},{"key":"3396_CR21","doi-asserted-by":"publisher","unstructured":"M\u00fcller RH, Alexiev U, Sinambela P, Keck CM. Nanostructured Lipid Carriers (NLC): The Second Generation of Solid Lipid Nanoparticles. Percutaneous Penetration Enhancers Chemical Methods in Penetration Enhancement. Berlin, Heidelberg: Springer Berlin Heidelberg; 2016. p. 161\u201385.\nhttps:\/\/doi.org\/10.1007\/978-3-662-47862-2_11","DOI":"10.1007\/978-3-662-47862-2_11"},{"key":"3396_CR22","doi-asserted-by":"publisher","unstructured":"Pyo S-M, M\u00fcller RH, Keck CM. Encapsulation by nanostructured lipid carriers. Nanoencapsulation Technologies for the Food and Nutraceutical Industries. Elsevier; 2017. p. 114\u201337.\nhttps:\/\/doi.org\/10.1016\/B978-0-12-809436-5.00004-5","DOI":"10.1016\/B978-0-12-809436-5.00004-5"},{"key":"3396_CR23","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics13040531","volume":"13","author":"AC Ortiz","year":"2021","unstructured":"Ortiz AC, Ya\u00f1ez O, Salas-Huenuleo E, Morales JO. Development of a nanostructured lipid carrier (NLC) by a low-energy method, comparison of release kinetics and molecular dynamics simulation. Pharmaceutics. 2021;13:531.\nhttps:\/\/doi.org\/10.3390\/pharmaceutics13040531\n.","journal-title":"Pharmaceutics"},{"key":"3396_CR24","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.jddst.2019.02.017","volume":"51","author":"VR Salvi","year":"2019","unstructured":"Salvi VR, Pawar P. Nanostructured lipid carriers (NLC) system: a novel drug targeting carrier. J Drug Deliv Sci Technol. 2019;51:255\u201367. https:\/\/doi.org\/10.1016\/j.jddst.2019.02.017.","journal-title":"J Drug Deliv Sci Technol"},{"key":"3396_CR25","doi-asserted-by":"publisher","first-page":"267","DOI":"10.4155\/cli.14.135","volume":"5","author":"P Ames","year":"2015","unstructured":"Ames P, Galor A. Cyclosporine ophthalmic emulsions for the treatment of dry eye: a review of the clinical evidence. Clin Investig Lond. 2015;5:267\u201385. https:\/\/doi.org\/10.4155\/cli.14.135.","journal-title":"Clin Investig Lond"},{"key":"3396_CR26","doi-asserted-by":"publisher","unstructured":"Mah F, Milner, Yiu, Donnenfeld E, Conway T, Hollander D. PERSIST: Physician\u2019s Evaluation of Restasis\u00ae Satisfaction in Second Trial of topical cyclosporine ophthalmic emulsion 0.05% for dry eye: a retrospective review. Clinical Ophthalmology. 2012;1971.\nhttps:\/\/doi.org\/10.2147\/OPTH.S30261","DOI":"10.2147\/OPTH.S30261"},{"key":"3396_CR27","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1089\/jop.2010.0059","volume":"26","author":"CS Foster","year":"2010","unstructured":"Foster CS, DaVanzo R, Flynn TE, McLeod K, Vogel R, Crockett RS. Durezol\u00ae (difluprednate ophthalmic emulsion 0.05%) compared with Pred Forte\u00ae 1% ophthalmic suspension in the treatment of endogenous anterior uveitis. J Ocul Pharmacol Ther. 2010;26:475\u201383. https:\/\/doi.org\/10.1089\/jop.2010.0059.","journal-title":"J Ocul Pharmacol Ther"},{"key":"3396_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.colsurfb.2020.111097","volume":"193","author":"A De Souza","year":"2020","unstructured":"De Souza A, Yukuyama MN, Barbosa EJ, Monteiro LM, Faloppa ACB, Calixto LA, et al. A new medium-throughput screening design approach for the development of hydroxymethylnitrofurazone (NFOH) nanostructured lipid carrier for treating leishmaniasis. Colloids Surf B Biointerfaces. 2020;193:111097. https:\/\/doi.org\/10.1016\/j.colsurfb.2020.111097.","journal-title":"Colloids Surf B Biointerfaces"},{"key":"3396_CR29","doi-asserted-by":"publisher","DOI":"10.3390\/PHARMACEUTICS14102221","author":"J Jesus","year":"2022","unstructured":"Jesus J, Louren\u00e7o FR, Ishida K, Barreto TL, Avino VC, Neto E, et al. Besifloxacin nanocrystal: towards an innovative ophthalmic preparation. Pharmaceutics. 2022. https:\/\/doi.org\/10.3390\/PHARMACEUTICS14102221.","journal-title":"Pharmaceutics"},{"key":"3396_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/J.IJPHARM.2022.122554","volume":"632","author":"MN Yukuyama","year":"2023","unstructured":"Yukuyama MN, Zuo J, Park C, Yousef M, Henostroza MAB, de Araujo GLB, et al. Biphasic dissolution combined with modified cylinder method\u2014a new promising method for dissolution test in drug-loaded nanoemulsions. Int J Pharm. 2023;632:122554. https:\/\/doi.org\/10.1016\/J.IJPHARM.2022.122554.","journal-title":"Int J Pharm"},{"key":"3396_CR31","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1208\/s12248-010-9185-1","volume":"12","author":"Z Yong","year":"2010","unstructured":"Yong Z, Meirong H, Jianping Z, Aifeng Z, Weize Li, Chengli Y, et al. DDSolver An add-in program modeling and comparison of drug dissolution profile. AAPS J. 2010;12:263\u201371.\nhttps:\/\/doi.org\/10.1208\/s12248-010-9185-1\n.","journal-title":"AAPS J"},{"key":"3396_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.colsurfa.2020.124755","volume":"597","author":"MAB Henostroza","year":"2020","unstructured":"Henostroza MAB, Curo Melo KJ, Nishitani Yukuyama M, L\u00f6benberg R, Araci Bou-Chacra N. Cationic rifampicin nanoemulsion for the treatment of ocular tuberculosis. Colloids Surf A Physicochem Eng Asp. 2020;597:124755.\nhttps:\/\/doi.org\/10.1016\/j.colsurfa.2020.124755\n.","journal-title":"Colloids Surf A Physicochem Eng Asp"},{"key":"3396_CR33","doi-asserted-by":"publisher","first-page":"4422","DOI":"10.1021\/nn103336a","volume":"5","author":"A Gianella","year":"2011","unstructured":"Gianella A, Jarzyna PA, Mani V, Ramachandran S, Calcagno C, Tang J, et al. Multifunctional nanoemulsion platform for imaging guided therapy evaluated in experimental cancer. ACS Nano. 2011;5:4422\u201333. https:\/\/doi.org\/10.1021\/nn103336a.","journal-title":"ACS Nano"},{"key":"3396_CR34","unstructured":"Clinical and Laboratory Standards Institute (CLSI). Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. 11th ed. CLSI standard M07. Berwyn, PA: Clinical and Laboratory Standards Institute; 2018."},{"key":"3396_CR35","unstructured":"Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). Stability testing of new drug substances and products Q1A(R2). Geneva: ICH; 2003."},{"key":"3396_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2021.105733","volume":"159","author":"V Katev","year":"2021","unstructured":"Katev V, Vinarov Z, Tcholakova S. Mechanisms of drug solubilization by polar lipids in biorelevant media. Eur J Pharm Sci. 2021;159:105733.\nhttps:\/\/doi.org\/10.1016\/j.ejps.2021.105733\n.","journal-title":"Eur J Pharm Sci"},{"key":"3396_CR37","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics13081287","volume":"13","author":"V Katev","year":"2021","unstructured":"Katev V, Tsibranska-Gyoreva S, Vinarov Z, Tcholakova S. Supersaturation and solubilization upon in vitro digestion of fenofibrate type I lipid formulations: effect of droplet size, surfactant concentration and lipid type. Pharmaceutics. 2021;13:1287.\nhttps:\/\/doi.org\/10.3390\/pharmaceutics13081287\n.","journal-title":"Pharmaceutics"},{"key":"3396_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2019.118918","volume":"576","author":"AB Kova\u010devi\u0107","year":"2020","unstructured":"Kova\u010devi\u0107 AB, M\u00fcller RH, Keck CM. Improved lipid screening and development of tacrolimus loaded nanostructured lipid carriers (NLC). Int J Pharm. 2020;576:118918. https:\/\/doi.org\/10.1016\/j.ijpharm.2019.118918.","journal-title":"Int J Pharm"},{"key":"3396_CR39","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.jsps.2020.01.010","volume":"28","author":"PA Makoni","year":"2020","unstructured":"Makoni PA, Ranchhod J, WaKasongo K, Khamanga SM, Walker RB. The use of quantitative analysis and Hansen solubility parameter predictions for the selection of excipients for lipid nanocarriers to be loaded with water soluble and insoluble compounds. Saudi Pharm J. 2020;28:308\u201315. https:\/\/doi.org\/10.1016\/j.jsps.2020.01.010.","journal-title":"Saudi Pharm J"},{"key":"3396_CR40","doi-asserted-by":"publisher","DOI":"10.3390\/ijms18071558","volume":"18","author":"G Georgiev","year":"2017","unstructured":"Georgiev G, Yokoi N, Nencheva Y, Peev N, Daull P. Surface chemistry interactions of Cationorm with films by human meibum and tear film compounds. Int J Mol Sci. 2017;18:1558. https:\/\/doi.org\/10.3390\/ijms18071558.","journal-title":"Int J Mol Sci"},{"key":"3396_CR41","doi-asserted-by":"publisher","unstructured":"Mudgil P. Antimicrobial Tear Lipids in the Ocular Surface Defense. Front Cell Infect Microbiol. 2022;12.\nhttps:\/\/doi.org\/10.3389\/fcimb.2022.866900","DOI":"10.3389\/fcimb.2022.866900"},{"key":"3396_CR42","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/j.jtos.2020.06.001","volume":"18","author":"RO Paananen","year":"2020","unstructured":"Paananen RO, Viitaja T, Ol\u017cy\u0144ska A, Ekholm FS, Moilanen J, Cwiklik L. Interactions of polar lipids with cholesteryl ester multilayers elucidate tear film lipid layer structure. Ocul Surf. 2020;18:545\u201353. https:\/\/doi.org\/10.1016\/j.jtos.2020.06.001.","journal-title":"Ocul Surf"},{"key":"3396_CR43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2012\/604204","volume":"2012","author":"F Lallemand","year":"2012","unstructured":"Lallemand F, Daull P, Benita S, Buggage R, Garrigue J-S. Successfully improving ocular drug delivery using the cationic nanoemulsion, Novasorb. J Drug Deliv. 2012;2012:1\u201316.\nhttps:\/\/doi.org\/10.1155\/2012\/604204\n.","journal-title":"J Drug Deliv"},{"key":"3396_CR44","doi-asserted-by":"publisher","unstructured":"Gupta MK. Crude Oil Receiving, Storage, and Handling. In: Monoj K. Gupta, editor. Practical Guide to Vegetable Oil Processing. Second Edition. Elsevier; 2017. p. 27\u201340.\nhttps:\/\/doi.org\/10.1016\/B978-1-63067-050-4.00003-9","DOI":"10.1016\/B978-1-63067-050-4.00003-9"},{"key":"3396_CR45","doi-asserted-by":"publisher","DOI":"10.1016\/j.colsurfa.2022.130039","volume":"654","author":"FL L\u00fcdtke","year":"2022","unstructured":"L\u00fcdtke FL, Stahl MA, Grimaldi R, Cardoso LP, Gigante ML, Ribeiro APB. High oleic sunflower oil and fully hydrogenated soybean oil nanostructured lipid carriers: development and characterization. Colloids Surf A Physicochem Eng Asp. 2022;654:130039.\nhttps:\/\/doi.org\/10.1016\/j.colsurfa.2022.130039\n.","journal-title":"Colloids Surf A Physicochem Eng Asp"},{"key":"3396_CR46","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.ijpharm.2016.06.135","volume":"511","author":"JJ Hakkarainen","year":"2016","unstructured":"Hakkarainen JJ, Reinisalo M, Ragauskas S, Sepp\u00e4nen A, Kaja S, Kalesnykas G. Acute cytotoxic effects of marketed ophthalmic formulations on human corneal epithelial cells. Int J Pharm. 2016;511:73\u20138. https:\/\/doi.org\/10.1016\/j.ijpharm.2016.06.135.","journal-title":"Int J Pharm"},{"key":"3396_CR47","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.ijpharm.2014.04.061","volume":"470","author":"A Leonardi","year":"2014","unstructured":"Leonardi A, Bucolo C, Romano GL, Platania CBM, Drago F, Puglisi G, et al. Influence of different surfactants on the technological properties and in vivo ocular tolerability of lipid nanoparticles. Int J Pharm. 2014;470:133\u201340. https:\/\/doi.org\/10.1016\/j.ijpharm.2014.04.061.","journal-title":"Int J Pharm"},{"key":"3396_CR48","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics10030159","volume":"10","author":"E Giuliano","year":"2018","unstructured":"Giuliano E, Paolino D, Fresta M, Cosco D. Mucosal applications of poloxamer 407-based hydrogels: an overview. Pharmaceutics. 2018;10:159.\nhttps:\/\/doi.org\/10.3390\/pharmaceutics10030159\n.","journal-title":"Pharmaceutics"},{"key":"3396_CR49","doi-asserted-by":"publisher","DOI":"10.1002\/adhm.202300319","author":"TB Gandek","year":"2023","unstructured":"Gandek TB, van der Koog L, Nagelkerke A. A comparison of cellular uptake mechanisms, delivery efficacy, and intracellular fate between liposomes and extracellular vesicles. Adv Healthc Mater. 2023. https:\/\/doi.org\/10.1002\/adhm.202300319.","journal-title":"Adv Healthc Mater"},{"key":"3396_CR50","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1080\/08927014.2016.1230849","volume":"32","author":"RE Sloup","year":"2016","unstructured":"Sloup RE, Cieza RJ, Needle DB, Abramovitch RB, Torres AG, Waters CM. Polysorbates prevent biofilm formation and pathogenesis ofEscherichia coliO104:H4. Biofouling. 2016;32:1131\u201340. https:\/\/doi.org\/10.1080\/08927014.2016.1230849.","journal-title":"Biofouling"},{"key":"3396_CR51","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1128\/AAC.00500-08","volume":"53","author":"CM Toutain-Kidd","year":"2009","unstructured":"Toutain-Kidd CM, Kadivar SC, Bramante CT, Bobin SA, Zegans ME. Polysorbate 80 inhibition ofPseudomonas aeruginosabiofilm formation and its cleavage by the secreted lipase LipA. Antimicrob Agents Chemother. 2009;53:136\u201345. https:\/\/doi.org\/10.1128\/AAC.00500-08.","journal-title":"Antimicrob Agents Chemother"},{"key":"3396_CR52","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-39997-3","volume":"9","author":"Y Ueda","year":"2019","unstructured":"Ueda Y, Mashima K, Miyazaki M, Hara S, Takata T, Kamimura H, et al. Inhibitory effects of polysorbate 80 on MRSA biofilm formed on different substrates including dermal tissue. Sci Rep. 2019;9:3128. https:\/\/doi.org\/10.1038\/s41598-019-39997-3.","journal-title":"Sci Rep"},{"key":"3396_CR53","doi-asserted-by":"publisher","DOI":"10.1002\/slct.202201477","author":"SS Patel","year":"2022","unstructured":"Patel SS, Patel HS, Kunjadiya A, Rao V, Sharma RK. Synthesis, characterization and antimicrobial activity of poloxamer\u2010assisted copper nanoparticles: investigating the effects of different concentrations of poloxamer 407. ChemistrySelect. 2022.\nhttps:\/\/doi.org\/10.1002\/slct.202201477\n.","journal-title":"ChemistrySelect"},{"key":"3396_CR54","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1007\/s11999-016-5211-7","volume":"475","author":"MA Harris","year":"2017","unstructured":"Harris MA, Beenken KE, Smeltzer MS, Haggard WO, Jennings AJ. Phosphatidylcholine coatings deliver local antimicrobials and reduce infection in a murine model: a preliminary study. Clin Orthop Relat Res. 2017;475:1847\u201353. https:\/\/doi.org\/10.1007\/s11999-016-5211-7.","journal-title":"Clin Orthop Relat Res"},{"key":"3396_CR55","doi-asserted-by":"publisher","DOI":"10.5312\/wjo.v7.i8.467","volume":"7","author":"JA Jennings","year":"2016","unstructured":"Jennings JA, Beenken KE, Skinner RA, Meeker DG, Smeltzer MS, Haggard WO, et al. Antibiotic-loaded phosphatidylcholine inhibits staphylococcal bone infection. World J Orthop. 2016;7:467. https:\/\/doi.org\/10.5312\/wjo.v7.i8.467.","journal-title":"World J Orthop"},{"key":"3396_CR56","doi-asserted-by":"publisher","first-page":"2886","DOI":"10.1021\/acs.langmuir.9b03944","volume":"36","author":"T Mehmood","year":"2020","unstructured":"Mehmood T, Ahmed A. Tween 80 and soya-lecithin-based food-grade nanoemulsions for the effective delivery of vitamin D. Langmuir. 2020;36:2886\u201392. https:\/\/doi.org\/10.1021\/acs.langmuir.9b03944.","journal-title":"Langmuir"},{"key":"3396_CR57","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2020.119831","volume":"589","author":"IF De Oliveira","year":"2020","unstructured":"De Oliveira IF, Barbosa EJ, Peters MCC, Henostroza MAB, Yukuyama MN, dos Santos Neto E, et al. Cutting-edge advances in therapy for the posterior segment of the eye: solid lipid nanoparticles and nanostructured lipid carriers. Int J Pharm. 2020;589:119831. https:\/\/doi.org\/10.1016\/j.ijpharm.2020.119831.","journal-title":"Int J Pharm"},{"key":"3396_CR58","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.ijbiomac.2015.12.077","volume":"85","author":"MS Baig","year":"2016","unstructured":"Baig MS, Ahad A, Aslam M, Imam SS, Aqil M, Ali A. Application of Box\u2013Behnken design for preparation of levofloxacin-loaded stearic acid solid lipid nanoparticles for ocular delivery: optimization, in vitro release, ocular tolerance, and antibacterial activity. Int J Biol Macromol. 2016;85:258\u201370. https:\/\/doi.org\/10.1016\/j.ijbiomac.2015.12.077.","journal-title":"Int J Biol Macromol"},{"key":"3396_CR59","doi-asserted-by":"publisher","DOI":"10.1016\/J.JCONREL.2025.113992","volume":"385","author":"B Ahmed","year":"2025","unstructured":"Ahmed B, Saini N, Barathi VA, Patravale VB, Shah RM, Kaur IP, et al. Innovative solid lipid nanoparticle formulations for ocular therapeutics and related patents: a systematic review. J Control Release. 2025;385:113992.\nhttps:\/\/doi.org\/10.1016\/J.JCONREL.2025.113992\n.","journal-title":"J Control Release"},{"key":"3396_CR60","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2023.114770","volume":"196","author":"H Han","year":"2023","unstructured":"Han H, Li S, Xu M, Zhong Y, Fan W, Xu J, et al. Polymer- and lipid-based nanocarriers for ocular drug delivery: current status and future perspectives. Adv Drug Deliv Rev. 2023;196:114770.\nhttps:\/\/doi.org\/10.1016\/j.addr.2023.114770\n.","journal-title":"Adv Drug Deliv Rev"},{"key":"3396_CR61","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1080\/10717544.2022.2048134","volume":"29","author":"Q Luo","year":"2022","unstructured":"Luo Q, Yang J, Xu H, Shi J, Liang Z, Zhang R, et al. Sorafenib-loaded nanostructured lipid carriers for topical ocular therapy of corneal neovascularization: development,\nin-vitro and\nin vivo study. Drug Deliv. 2022;29:837\u201355.\nhttps:\/\/doi.org\/10.1080\/10717544.2022.2048134\n.","journal-title":"Drug Deliv"},{"key":"3396_CR62","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.ijpharm.2018.01.012","volume":"538","author":"H Qu","year":"2018","unstructured":"Qu H, Wang J, Wu Y, Zheng J, Krishnaiah YSR, Absar M, et al. Asymmetric flow field flow fractionation for the characterization of globule size distribution in complex formulations: a cyclosporine ophthalmic emulsion case. Int J Pharm. 2018;538:215\u201322.\nhttps:\/\/doi.org\/10.1016\/j.ijpharm.2018.01.012\n.","journal-title":"Int J Pharm"},{"key":"3396_CR63","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1089\/jop.2015.0054","volume":"32","author":"P Daull","year":"2016","unstructured":"Daull P, Feraille L, Elena P-P, Garrigue J-S. Comparison of the anti-inflammatory effects of artificial tears in a rat model of corneal scraping. J Ocul Pharmacol Ther. 2016;32:109\u201318.\nhttps:\/\/doi.org\/10.1089\/jop.2015.0054\n.","journal-title":"J Ocul Pharmacol Ther"},{"issue":"2","key":"3396_CR64","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/S0928-0987(01)00095-1","volume":"13","author":"P Costa","year":"2001","unstructured":"Costa P, Sousa Lobo JM, Elsevier. Modeling and comparison of dissolution profiles. Eur J Pharm Sci. 2001;13(2):123\u201333.\nhttps:\/\/doi.org\/10.1016\/S0928-0987(01)00095-1\n.","journal-title":"Eur J Pharm Sci"},{"key":"3396_CR65","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics12060582","volume":"12","author":"Y-S Lin","year":"2020","unstructured":"Lin Y-S, Tsay R-Y. Drug release from a spherical matrix theoretical analysis for a finite dissolution rate affected by geometric shape of dispersed drugs. Pharmaceutics. 2020;12:582.","journal-title":"Pharmaceutics"},{"key":"3396_CR66","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1007\/s40005-017-0320-1","volume":"47","author":"G-H Son","year":"2017","unstructured":"Son G-H, Lee B-J, Cho C-W. Mechanisms of drug release from advanced drug formulations such as polymeric-based drug-delivery systems and lipid nanoparticles. J Pharm Investig. 2017;47:287\u201396.\nhttps:\/\/doi.org\/10.1007\/s40005-017-0320-1\n.","journal-title":"J Pharm Investig"},{"key":"3396_CR67","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1039\/D2NA00795A","volume":"5","author":"MS Khan","year":"2023","unstructured":"Khan MS, Baskoy SA, Yang C, Hong J, Chae J, Ha H, et al. Lipid-based colloidal nanoparticles for applications in targeted vaccine delivery. Nanoscale Adv. 2023;5:1853\u201369. https:\/\/doi.org\/10.1039\/D2NA00795A.","journal-title":"Nanoscale Adv"},{"key":"3396_CR68","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/S0378-5173(96)04731-X","volume":"144","author":"RH M\u00fcller","year":"1996","unstructured":"M\u00fcller RH, R\u00fchl D, Runge SA. Biodegradation of solid lipid nanoparticles as a function of lipase incubation time. Int J Pharm. 1996;144:115\u201321. https:\/\/doi.org\/10.1016\/S0378-5173(96)04731-X.","journal-title":"Int J Pharm"},{"key":"3396_CR69","doi-asserted-by":"publisher","unstructured":"Porbaha Pedram, Ansari Ramin, Kiafar Mohammad Reza, Bashiry Rahman, Khazaei Mohammad Mehdi, Dadbakhsh Amirhossein, et al. A comparative mathematical analysis of durg release from lipid based nanoparticles. AAPS PharmSciTech. 2024;25:208.\nhttps:\/\/doi.org\/10.1208\/s12249-024-02922-7","DOI":"10.1208\/s12249-024-02922-7"},{"key":"3396_CR70","unstructured":"United States Pharmacopeia and National Formulary (USP 40\u2013NF 35). <785> Osmolality and Osmolarity. Rockville, MD: United States Pharmacopeial Convention; 2017."},{"key":"3396_CR71","doi-asserted-by":"publisher","first-page":"3719","DOI":"10.1021\/acs.molpharmaceut.1c00650","volume":"18","author":"A Gawin-Miko\u0142ajewicz","year":"2021","unstructured":"Gawin-Miko\u0142ajewicz A, Nartowski KP, Dyba AJ, Go\u0142kowska AM, Malec K, Karolewicz B. Ophthalmic nanoemulsions: from composition to technological processes and quality control. Mol Pharm. 2021;18:3719\u201340. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.1c00650.","journal-title":"Mol Pharm"},{"key":"3396_CR72","doi-asserted-by":"publisher","unstructured":"Paredes da Rocha N, de Souza A, Nishitani Yukuyama M, Lopes Barreto T, de O. Macedo L, L\u00f6benberg R, et al. Highly water-soluble dapsone nanocrystals: Towards innovative preparations for an undermined drug. Int J Pharm. 2023;630:122428.\nhttps:\/\/doi.org\/10.1016\/j.ijpharm.2022.122428","DOI":"10.1016\/j.ijpharm.2022.122428"},{"key":"3396_CR73","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-99337-6","volume":"15","author":"FJ Edzeamey","year":"2025","unstructured":"Edzeamey FJ, Ramchunder Z, McCarthy RR, Virmouni SA. Galleria mellonellaas a drug discovery model to study oxidative stress. Sci Rep. 2025;15:15218. https:\/\/doi.org\/10.1038\/s41598-025-99337-6.","journal-title":"Sci Rep"},{"key":"3396_CR74","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/j.chemosphere.2018.01.175","volume":"198","author":"E Allegra","year":"2018","unstructured":"Allegra E, Titball RW, Carter J, Champion OL. Galleria mellonellalarvae allow the discrimination of toxic and non-toxic chemicals. Chemosphere. 2018;198:469\u201372. https:\/\/doi.org\/10.1016\/j.chemosphere.2018.01.175.","journal-title":"Chemosphere"},{"key":"3396_CR75","doi-asserted-by":"publisher","unstructured":"Ivanov I, Akhmedova D, Koroleva Y, Shatalov D. Sterility of Ophthalmic Solutions as a Factor in the Evolution of Primary Packaging for Eye Drops: A Literature Review. Sciences of Pharmacy. 2024;3:39\u201349.\nhttps:\/\/doi.org\/10.58920\/sciphar0301211","DOI":"10.58920\/sciphar0301211"},{"key":"3396_CR76","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/9783527631193.ch1","volume-title":"Colloid Stability","author":"T Tadros","year":"2010","unstructured":"Tadros T. General Principles of Colloid Stability and the Role of Surface Forces. In: Colloid Stability. Wiley; 2010. p. 1\u201322.\nhttps:\/\/doi.org\/10.1002\/9783527631193.ch1\n."},{"key":"3396_CR77","doi-asserted-by":"publisher","unstructured":"Selvamani V. Stability Studies on Nanomaterials Used in Drugs. In: Shyam S. Mohapatra, Shivendu Ranjan, Nandita Dasgupta, Raghvendra Kumar Mishra, Sabu Thomas, editors. In Micro and Nano Technologies, Characterization and Biology of Nanomaterials for Drug Delivery. Elsevier; 2019. p. 425\u201344.\nhttps:\/\/doi.org\/10.1016\/B978-0-12-814031-4.00015-5","DOI":"10.1016\/B978-0-12-814031-4.00015-5"},{"key":"3396_CR78","doi-asserted-by":"publisher","unstructured":"Liu Z, Fu R, Yuying Y. Preparation and evaluation of stable nanofluids for heat transfer application. Advances in Nanofluid Heat Transfer [Internet]. Elsevier; 2022 [cited 2026 Jan 31];25\u201357.\nhttps:\/\/doi.org\/10.1016\/B978-0-323-88656-7.00013-1","DOI":"10.1016\/B978-0-323-88656-7.00013-1"}],"container-title":["AAPS PharmSciTech"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-026-03396-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1208\/s12249-026-03396-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-026-03396-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T08:49:50Z","timestamp":1780390190000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1208\/s12249-026-03396-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,10]]},"references-count":78,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["3396"],"URL":"https:\/\/doi.org\/10.1208\/s12249-026-03396-5","relation":{},"ISSN":["1530-9932"],"issn-type":[{"value":"1530-9932","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,10]]},"assertion":[{"value":"26 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"176"}}